MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
The last earnings update was 70 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
MediciNova. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
MediciNova's earnings available for a low price, and how does
this compare to other companies in the same industry?
MediciNova is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if MediciNova is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
MediciNova's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Yuichi Iwaki, M.D., Ph.D. is a Co-Founder of MediciNova Inc. and has been its Chief Executive Officer and President since March 2006. Dr. Iwaki is a Partner of Biotech Healthcare Partners, Inc. He was an Advisor of JAFCO Co., Ltd. He has been advising pharmaceutical companies and venture capital funds regarding research and investment strategies for over 30 years and is a Board Member of several biotechnology companies. He served as an Acting Chief Financial Officer and Acting Chief Accounting Officer of MediciNova Inc. from November 8, 2013 to April 2014. He served as an Acting Chief Executive Officer of MediciNova since September 2005 and its Acting Chief Financial Officer from September 2005 to November 2011. He served as the Chairman of MediciNova Inc., from September 26, 2000 to March 30, 2007, became its Executive Chairman in July 2005. He was a Director of Avigen since November 1994 until 2008 Dr. Iwaki serves as a Director at Biotech Healthcare Partners, Inc. He has been an Executive Director of MediciNova since September 26, 2000. From September 2001 until January 2007, Dr. Iwaki also served as consultant at MediciNova Inc. in connection with financing transactions and business development activities. He is a Director of the Transplantation Immunology and Immunogenetic Laboratory since 1992 and Intercept Pharmaceuticals, Inc. Dr. Iwaki is also a visiting professor at the Toho University School of Medicine. He is also a Member of Advisory Board of Two River Group Holdings, LLC. He served as a Director at Antyra, Inc. He has held three professorships at University of Southern California School of Medicine in the departments of urology, pathology and surgery since 1992. He is a Professor in the Department of Urology, Surgery and Pathology at Keck School of Medicine. In addition, Dr. Iwaki holds visiting professorships at the University of California, Irvine, School of Medicine; Nihon University School of Medicine, Kyushu University; and the Tokyo Women's Medical School in Japan. Prior to joining the University of Southern California School of Medicine faculty in 1992, he held professorships at the University of Pittsburgh in the Departments of Surgery and Pathology from 1989 through 1991. Dr. Iwaki is the author of more than 200 peer-reviewed publications and more than 40 books. He received a Ph.D. and an M.D. from Sapporo Medicine School in Sapporo.
Yuichi's compensation has increased whilst company is loss making.
Yuichi's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the MediciNova management team is over 5 years, this suggests they are a seasoned and experienced team.
Chief Medical Officer
Chief Financial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the MediciNova board of directors is about average.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective ß2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.